Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1957 1
1965 1
1968 1
1970 2
1971 1
1972 1
1973 2
1974 4
1975 2
1976 4
1977 3
1978 8
1979 3
1980 7
1981 4
1982 5
1983 10
1984 16
1985 9
1986 12
1987 23
1988 43
1989 63
1990 95
1991 163
1992 123
1993 140
1994 136
1995 136
1996 158
1997 109
1998 117
1999 119
2000 86
2001 101
2002 76
2003 64
2004 62
2005 70
2006 56
2007 59
2008 48
2009 70
2010 71
2011 66
2012 60
2013 72
2014 64
2015 66
2016 80
2017 80
2018 83
2019 93
2020 98
2021 132
2022 70
2023 112
2024 101
2025 100
2026 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,427 results

Results by year

Filters applied: . Clear all
Page 1
Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults.
Zhou S, Aitken SL. Zhou S, et al. JAMA. 2023 Jul 11;330(2):182-183. doi: 10.1001/jama.2023.9844. JAMA. 2023. PMID: 37358837
This JAMA Insights Clinical Update discusses current recommendations regarding prevention of Pneumocystis pneumonia in patients who are immunocompromised....
This JAMA Insights Clinical Update discusses current recommendations regarding prevention of Pneumocystis pneumonia in …
Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.
Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, Thursky KA. Cooley L, et al. Intern Med J. 2014 Dec;44(12b):1350-63. doi: 10.1111/imj.12599. Intern Med J. 2014. PMID: 25482745 Review.
Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. ...Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available... …
Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. ...Tr …
Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, Rjeily MB, Butler-Laporte G, McDonald EG, Lee TC. Prosty C, et al. Clin Microbiol Infect. 2024 Jul;30(7):866-876. doi: 10.1016/j.cmi.2024.03.037. Epub 2024 Apr 6. Clin Microbiol Infect. 2024. PMID: 38583518 Free article.
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection among people living with HIV (PWH), particularly among new and untreated cases. Several regimens are available for the prophylaxis of PCP, including trimethoprim-sulfametho …
BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a common opportunistic infection among people living with HIV (PWH), par …
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).
Classen AY, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff LD, Alakel N, Christopeit M, Krause SW, Mayer K, Neumann S, Cornely OA, Penack O, Weißinger F, Wolf HH, Vehreschild JJ. Classen AY, et al. Ann Hematol. 2021 Jun;100(6):1603-1620. doi: 10.1007/s00277-021-04452-9. Epub 2021 Apr 13. Ann Hematol. 2021. PMID: 33846857 Free PMC article.
Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new research reshapes our und …
Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections a …
Pneumocystis jirovecii: a review with a focus on prevention and treatment.
Weyant RB, Kabbani D, Doucette K, Lau C, Cervera C. Weyant RB, et al. Expert Opin Pharmacother. 2021 Aug;22(12):1579-1592. doi: 10.1080/14656566.2021.1915989. Epub 2021 Apr 19. Expert Opin Pharmacother. 2021. PMID: 33870843 Review.
Introduction: Pneumocystis jirovecii (PJ) is an opportunistic fungal pathogen that can cause severe pneumonia in immunocompromised hosts. Risk factors for Pneumocystis jirovecii pneumonia (PJP) include HIV, organ transplant, malignancy, certain inflamm …
Introduction: Pneumocystis jirovecii (PJ) is an opportunistic fungal pathogen that can cause severe pneumonia in immunocomprom …
Pneumocystis jiroveci.
Fishman JA. Fishman JA. Semin Respir Crit Care Med. 2020 Feb;41(1):141-157. doi: 10.1055/s-0039-3399559. Epub 2020 Jan 30. Semin Respir Crit Care Med. 2020. PMID: 32000290 Review.
Subclinical infection or colonization may occur. Pneumocystis pneumonia occurs most often within 6 months of organ transplantation and with intensified or prolonged immunosuppression, notably with corticosteroids. ...Adjunctive corticosteroids may be useful early in …
Subclinical infection or colonization may occur. Pneumocystis pneumonia occurs most often within 6 months of organ transplanta …
Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
Sierra CM, Daiya KC. Sierra CM, et al. Pharmacotherapy. 2022 Nov;42(11):858-867. doi: 10.1002/phar.2733. Epub 2022 Oct 25. Pharmacotherapy. 2022. PMID: 36222368 Free PMC article.
Patients with inflammatory bowel disease (IBD) are at increased risk of developing Pneumocystis jirovecii pneumonia (PJP) than the general population. Many medications utilized for the treatment of IBD affect the immune system, potentially further increasing the ris …
Patients with inflammatory bowel disease (IBD) are at increased risk of developing Pneumocystis jirovecii pneumonia (PJP) than …
Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?
Kim JY, Choi SR, Park JK, Lee EY, Lee EB, Park JW. Kim JY, et al. Arthritis Rheumatol. 2025 Sep;77(9):1263-1272. doi: 10.1002/art.43167. Epub 2025 May 8. Arthritis Rheumatol. 2025. PMID: 40176385 Free PMC article.
OBJECTIVE: Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing fo …
OBJECTIVE: Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is ef …
Pneumocystis jirovecii pneumonia in people living with HIV: a review.
McDonald EG, Afshar A, Assiri B, Boyles T, Hsu JM, Khuong N, Prosty C, So M, Sohani ZN, Butler-Laporte G, Lee TC. McDonald EG, et al. Clin Microbiol Rev. 2024 Mar 14;37(1):e0010122. doi: 10.1128/cmr.00101-22. Epub 2024 Jan 18. Clin Microbiol Rev. 2024. PMID: 38235979 Free PMC article. Review.
Pneumocystis jirovecii is a ubiquitous opportunistic fungus that can cause life-threatening pneumonia. People with HIV (PWH) who have low CD4 counts are one of the populations at the greatest risk of Pneumocystis jirovecii pneumonia (PCP). While guidel …
Pneumocystis jirovecii is a ubiquitous opportunistic fungus that can cause life-threatening pneumonia. People with HIV (PWH) w …
Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases.
Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D. Ghembaza A, et al. Chest. 2020 Dec;158(6):2323-2332. doi: 10.1016/j.chest.2020.05.558. Epub 2020 Jun 2. Chest. 2020. PMID: 32502592 Review.
Patients with autoimmune and/or inflammatory diseases (AIIDs) are prone to serious infectious complications such as Pneumocystis jirovecii pneumonia (PJP). In non-HIV patients, the prognosis is poorer, and diagnostic tests are of lower sensitivity. ...No standard gu …
Patients with autoimmune and/or inflammatory diseases (AIIDs) are prone to serious infectious complications such as Pneumocystis jiro …
3,427 results